LARSEN & TOUBRO

RESEARCH: GOLDMAN SACHS RATING: BUY CMP: 1652

Goldman Sachs underpins the ''Buy'' rating on Larsen & Toubro with a target price of 2,006. L&T reported Q4FY11 sales of 15,380 crore and adjusted net profit of 1,500 crore, mostly in line with the consensus estimates. Total order inflows for the year grew by 15% y-o-y. FY11 results on a consolidated basis were also mostly in line with the estimates. The company recognised about 5,900 crore in orders from the Hyderabad Metro project in Q4FY11. Though industry-wide order inflows could remain weak at least through Q2FY12E, the impact of any such weakness on L&T could be muted, given its strong order backlog. Go ldman Sachs revises the FY12E-13E EPS by 0.4-0.5%, adjusting for the better-than-expected margins seen in Q4FY11. Goldman Sachs continues to factor in a 50-basis point decline in EBIT margins in FY12E versus FY11, in line with the company''s guidance.

OBEROI REALTY

RESEARCH: CITIGROUP RATING: BUY CMP: 230

Citigroup initiates ''Buy'' rating on Oberoi Realty. Oberoi has a strong and diversified land portfolio of about 19 msf, spread largely across four locations in Mumbai. Oberoi, debt free since FY10, has a net cash balance of 1,460 crore, a positive in uncertain times. Development book is uniquely front-ended, with about 65% of gross NAV likely to be delivered by 2015. This feature should stand out in challenging times like now, making Oberoi a preferred pick. Oberoi forecasts 29%/26% CAGR in revenue/EBITDA respectively, based on the front-ended development book. A growing leasing and hospitality portfolio enhances the annuity stream, providing stability to cash flows. Oberoi stands out on the ?safety? perception in the sector. It has 1,460 crore of cash, negative net D/E since FY07 and likely the best ROE in the sector. Its impressive disclosures, as seen in the last two quarters, comfort investors as well.

SBI

RESEARCH: MORGAN STANLEY RATING: UNDERWEIGHT CMP: 2322

SBI announced weak numbers for March 2011. The lower results were driven by sharp NIM contraction during the quarter (38 bps Q-o-Q) and large provisions. Moreover, the bank took a 8,000-crore hit through book value toward pension. This brought tier 1 ratio to 7.8%. The slippage rate spiked to 3.1% of loans in Q4 from 2.3% last quarter. This looks very high to Morgan Stanley, and they are being conservative and not changing their underlying LLP estimates at this time. Morgan Stanley, however, is building in a 1,500 crore hit to reflect the change in RBI regulations. However, if rates remain at current levels (lending rates are the highest in 10 years) and the economy slows, then credit costs could rise sharply (especially given the large unseasoned infrastructure loan book). Morgan Stanley''s new EPS for 2012E is 3% lower as they reduce pension costs (already reflected in lower book). The new target price implies about 17% downside from current levels. The stock would trade at 8.1x FY2012E core P/E and 1.3x core book.

ORCHID PHARMA

RESEARCH: MACQUARIE RATING: OUTPERFORM CMP: 283

Macquarie maintains ''Outperform'' rating on Orchid Pharmaceuticals with a target price of 415. Orchid reported FY11 sales of 1,720 crore, EBITDA of Rs420 crore PAT of Rs156 crore. Results were well ahead of the estimates and company guidance. Orchid has FCCB repayment ($163m) due in February 2012. Orchid announced that a fund-raising resolution of a maximum 1,000 crore has been considered by the board. Macquarie has already factored equity dilution of about 15 m shares (equivalent to FCCB equity conversion) into their model. They expect any shortfall to be met by additional debt. The upcoming launch of Imipenem by HSP and supply of bulk for Add Vantage device should boost growth in FY12. Given the limited competition for the products under contract, Macquarie expects this to be a significant growth driver, with EBITDA margin more than 30% Receivable/Inventory days came down to 105/126 days.

SINTEX INDUSTRIES

RESEARCH: UBS INVESTMENT RATING: BUY CMP: 173

UBS Investment initiates coverage on ''Sintex'' Industries with a Buy'' rating and price target of 240. Sintex Industries (SINT), a diversified industrial company, is a key beneficiary of the government''s non-cyclical and growing social spending on education, lowcost housing, healthcare and rural infrastructure in India. Its building products business has scale advantages and its custom moulding business looks well positioned to benefit from a recovery in the industrial cycle, and synergies from its acquisitions and their scaling up. UBS thinks concerns over SINT''s capital discipline have been largely allayed by sharply lower working capital in FY11, divestment of unrelated investments, and management''s focus on the core business. A growing monolithic construction order book provides growth and margin visibility in the near term. UBS thinks an improving growth trajectory, a stronger balance sheet (lower working capital, debt:equity at 0.3x in FY13E) and positive free cash flow from FY11E should support a re-rating of the stock.